Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
MEI Pharma Inc (MEIP) is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies, with an emphasis on oral treatments targeting specific cancer mechanisms. This page provides investors and industry observers with timely updates on the company’s clinical trials, regulatory milestones, financial performance, and strategic partnerships.
As a centralized resource for MEI Pharma news, this page aggregates press releases, earnings reports, and scientific updates related to its pipeline candidates including zandelisib (PI3K delta inhibitor) and ME-344 (mitochondrial inhibitor). Users can track progress across clinical development stages, from Phase 1 safety data to late-stage trial results.
The curated news collection serves investors seeking to monitor MEIP’s operational progress, partnership announcements with pharmaceutical companies, and presentations at major medical conferences. Content is organized chronologically and categorized for efficient navigation, ensuring stakeholders stay informed about developments impacting the company’s valuation and scientific trajectory.
Bookmark this page for direct access to MEI Pharma’s official communications, including FDA correspondence updates and analyses of trial data. Regular visitors gain a comprehensive view of the company’s position within the competitive oncology therapeutics sector without promotional bias.
MEI Pharma, a clinical-stage pharmaceutical company, reported positive results for the third quarter fiscal year 2024, highlighting promising clinical data for voruciclib and ME-344. The ongoing Phase 1 study evaluating voruciclib plus venetoclax in R/R AML patients showed anti-leukemic activity, with complete responses and significant decreases in Mcl-1 levels. MEI's Board of Directors is focused on advancing the voruciclib program, with a cash balance of $56.6 million. MEI also initiated research on a new ME-344 formulation and decided to prioritize clinical development of voruciclib. Financially, MEI had no debt, $56.6 million in cash, and believes its cash balance is sufficient for the next 12 months.
FAQ
What is the current stock price of Mei Pharma (MEIP)?
What is the market cap of Mei Pharma (MEIP)?
